Abstract

Angiotensin-converting enzyme 2 (ACE2) has been implicated in the pathogenesis of chronic kidney disease (CKD) and is a membrane receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease (COVID-19), whereas transmembrane protease, serine 2 (TMPRSS2) is involved in viral attachment. Together, tissue expression of ACE2 and TMPRSS2 may determine infection. Sex, age, body mass index (BMI), and CKD are clinical risk factors for COVID-19 severity, but the relationships between kidney ACE2 and TMPRSS2 expression and these clinical variables are unknown. Accordingly, we obtained renal tubulointerstitial and glomerular microarray expression data and clinical variables from healthy living donors (HLD) and patients with CKD from the European Renal cDNA Bank. ACE2 expression was similar in the tubulointerstitium of the two groups, but greater in females than males in HLD (P = 0.005) and CKD (P < 0.0001). ACE2 expression was lower in glomeruli of CKD patients compared to HLD (P = 0.0002) and lower in males than females. TMPRSS2 expression was similar in the tubulointerstitium but lower in glomeruli of CKD patients compared to HLD (P < 0.0001). There was a strong relationship between ACE2 and TMPRSS2 expression in the glomerulus (r = 0.51, P < 0.0001). In CKD, there was a relationship between tubulointerstitial ACE2 expression and estimated glomerular filtration rate (r = 0.36, P < 0.0001) and age (r = -0.17, P = 0.03), but no relationship with BMI. There were no relationships between TMPRSS2 expression and clinical variables. Genes involved in inflammation (CCL2, IL6, and TNF) and fibrosis (COL1A1, TGFB1, and FN1) were inversely correlated with ACE2 expression. In summary, kidney expression of ACE2 and TMPRSS2 differs in HLD and CKD. ACE2 is related to sex and eGFR. ACE2 is also associated with expression of genes implicated in inflammation and fibrosis.

Highlights

  • Angiotensin-converting enzyme 2 (ACE2) modifies angiotensin peptide metabolism and affects the progression of chronic kidney disease (CKD) [1]

  • There are few studies of ACE2 expression in CKD in humans [26, 28, 29], and interestingly, studies have shown that ACE2 is a receptor for SARS-CoV and SARS-CoV-2 [12, 34]

  • Loss of ACE2 accelerates the progression of experimental kidney disease [35,36,37]; we studied the relationships between kidney ACE2 expression and genes implicated in inflammation and fibrosis in CKD

Read more

Summary

Introduction

Angiotensin-converting enzyme 2 (ACE2) modifies angiotensin peptide metabolism and affects the progression of chronic kidney disease (CKD) [1]. Kidney ACE2 expression in CKD predominantly expressed in proximal tubules and glomerular podocytes [2, 3]. ACE2 converts angiotensin (Ang) I to Ang-(1–9) and Ang II to Ang-(1–7) [4, 5]. As a proinflammatory and profibrogenic peptide, Ang II is a major contributor to the progression of CKD [6, 7]. ACE2, which is capable of reducing Ang II and promoting Ang-(1–7), serves as a key protective enzyme by reducing oxidative stress, inflammation, and fibrosis [11]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call